407 related articles for article (PubMed ID: 9816045)
1. Absence of p53 autoantibodies in sera from glioma patients.
Rainov NG; Dobberstein KU; Fittkau M; Bahn H; Holzhausen HJ; Gantchev L; Burkert W
Clin Cancer Res; 1995 Jul; 1(7):775-81. PubMed ID: 9816045
[TBL] [Abstract][Full Text] [Related]
2. Anti-P53 antibodies in Brazilian brain tumor patients.
Fonseca RF; Kawamura MT; Oliveira JA; Teixeira A; Alves G; Carvalho Mda G
Genet Mol Res; 2003 Jun; 2(2):185-90. PubMed ID: 14966683
[TBL] [Abstract][Full Text] [Related]
3. Ethnicity delineates different genetic pathways in malignant glioma.
Chen P; Aldape K; Wiencke JK; Kelsey KT; Miike R; Davis RL; Liu J; Kesler-Diaz A; Takahashi M; Wrensch M
Cancer Res; 2001 May; 61(10):3949-54. PubMed ID: 11358811
[TBL] [Abstract][Full Text] [Related]
4. [Mutations of p53 gene in 41 cases of human brain gliomas].
Cui W; Kong X; Cao HL; Wang X; Gao JF; Wu RL; Wang XC
Ai Zheng; 2008 Jan; 27(1):8-11. PubMed ID: 18184456
[TBL] [Abstract][Full Text] [Related]
5. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies.
Watanabe K; Sato K; Biernat W; Tachibana O; von Ammon K; Ogata N; Yonekawa Y; Kleihues P; Ohgaki H
Clin Cancer Res; 1997 Apr; 3(4):523-30. PubMed ID: 9815715
[TBL] [Abstract][Full Text] [Related]
6. p53 autoantibodies can be indicative of the development of breast cancer relapse.
Regele S; Vogl FD; Kohler T; Kreienberg R; Runnebaum IB
Anticancer Res; 2003; 23(1B):761-4. PubMed ID: 12680180
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic significance of p53 autoantibodies in serum of patients with breast carcinoma].
Huober J; Sprenger H; Costa SD; Zentgraf H; Schmid H; Kaufmann M; Bastert G
Zentralbl Gynakol; 1996; 118(10):560-4. PubMed ID: 8999710
[TBL] [Abstract][Full Text] [Related]
8. Detection of p53 gene mutations in human brain tumors by single-strand conformation polymorphism analysis of polymerase chain reaction products.
Mashiyama S; Murakami Y; Yoshimoto T; Sekiya T; Hayashi K
Oncogene; 1991 Aug; 6(8):1313-8. PubMed ID: 1886708
[TBL] [Abstract][Full Text] [Related]
9. Humoral response to p53 is associated with conserved domains II and IV mutations in human colorectal cancer: a case-control study in Taiwan.
Wu CM; Tang R; Chen JR; Wu MC; Chien HT; Changchien CR; Hsieh LL
Oncol Rep; 2004 Nov; 12(5):1045-51. PubMed ID: 15492791
[TBL] [Abstract][Full Text] [Related]
10. p53 mutations in human malignant gliomas: comparison of loss of heterozygosity with mutation frequency.
Frankel RH; Bayona W; Koslow M; Newcomb EW
Cancer Res; 1992 Mar; 52(6):1427-33. PubMed ID: 1347252
[TBL] [Abstract][Full Text] [Related]
11. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
[TBL] [Abstract][Full Text] [Related]
12. Human gliomas with wild-type p53 express bcl-2.
Alderson LM; Castleberg RL; Harsh GR; Louis DN; Henson JW
Cancer Res; 1995 Mar; 55(5):999-1001. PubMed ID: 7867012
[TBL] [Abstract][Full Text] [Related]
13. Correlation of p53 immunoreactivity and sequencing in patients with glioma.
Kyritsis AP; Xu R; Bondy ML; Levin VA; Bruner JM
Mol Carcinog; 1996 Jan; 15(1):1-4. PubMed ID: 8561860
[TBL] [Abstract][Full Text] [Related]
14. Reappraisal of p53 mutations in human malignant astrocytic neoplasms by p53 functional assay: comparison with conventional structural analyses.
Tada M; Iggo RD; Waridel F; Nozaki M; Matsumoto R; Sawamura Y; Shinohe Y; Ikeda J; Abe H
Mol Carcinog; 1997 Mar; 18(3):171-6. PubMed ID: 9115587
[TBL] [Abstract][Full Text] [Related]
15. Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors.
Ren ZP; Olofsson T; Qu M; Hesselager G; Soussi T; Kalimo H; Smits A; Nistér M
J Neuropathol Exp Neurol; 2007 Oct; 66(10):944-54. PubMed ID: 17917588
[TBL] [Abstract][Full Text] [Related]
16. Development of antibodies against p53 in lung cancer patients appears to be dependent on the type of p53 mutation.
Winter SF; Minna JD; Johnson BE; Takahashi T; Gazdar AF; Carbone DP
Cancer Res; 1992 Aug; 52(15):4168-74. PubMed ID: 1322237
[TBL] [Abstract][Full Text] [Related]
17. Mutations of the p53 gene in gliomas from Malay patients.
Jafri A; Aziz MY; Ros S; Nizam I
Med J Malaysia; 2003 Jun; 58(2):236-42. PubMed ID: 14569744
[TBL] [Abstract][Full Text] [Related]
18. Immunofluorometric assay of p53 protein versus sequencing of p53 exons 5 to 9 for the detection of p53 abnormalities in ovarian carcinoma.
Lianidou ES; Levesque MA; Katsaros D; Angelopoulou K; Yu H; Genta F; Arisio R; Massobrio M; Bharaj B; Diamandis EP
Anticancer Res; 1999; 19(1B):749-56. PubMed ID: 10216487
[TBL] [Abstract][Full Text] [Related]
19. p53 mutation is infrequent in clear cell carcinoma of the ovary.
Ho ES; Lai CR; Hsieh YT; Chen JT; Lin AJ; Hung MH; Liu FS
Gynecol Oncol; 2001 Feb; 80(2):189-93. PubMed ID: 11161858
[TBL] [Abstract][Full Text] [Related]
20. The circulating auto-antibodies to p53 protein in the follow-up of lymphoma patients.
Jezersek B; Rudolf Z; Novakovic S
Oncol Rep; 2001; 8(1):77-81. PubMed ID: 11115573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
